SCHEMBL3361882

SCHEMBL3361882

COc1ccccc1OC(=O)CCC(=O)Oc1ccccc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.59
▸ MAPT P10636 4/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ ALDH1A1 P00352 3/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ POLB P06746 2/20 0.56
▸ LMNA P02545 3/20 0.55
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ CA4 P22748 1/20 0.54
▸ CA7 P43166 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ CA14 Q9ULX7 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ KDM4E B2RXH2 2/20 0.49
▸ RECQL P46063 1/20 0.49
▸ HSD17B10 Q99714 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3361878 0.93 LMNA (0.62) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL28956722 0.93 KMT2A (0.54) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL31453791 0.93 KMT2A (0.54) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL28936425 0.92 KMT2A (0.56) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL5701570 0.92 KMT2A (0.56) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL31053826 0.90 L3MBTL1 (0.56) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL4642495 0.90 KMT2A (0.55) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL1792324 0.90 L3MBTL1 (0.56) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL17518984 0.90 KMT2A (0.55) KMT2AMAPTMEN1ALDH1A1L3MBTL1
SCHEMBL4641973 0.89 KMT2A (0.54) KMT2AMAPTMEN1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2237683-B1 METHOD OF FLAVORING GIVAUDAN SA (CH) 2015-11-11 — — EP disclosed
CN-101969791-B seasoning method GIVAUDAN SA 2013-10-30 — — CN disclosed
US-20130177688-A1 Method of Flavoring GIVAUDAN S.A. (CH) 2013-07-11 — — US disclosed
CN-101969791-A seasoning method GIVAUDAN SA 2011-02-09 — — CN disclosed
EP-2237683-A2 METHOD OF FLAVORING Givaudan SA (CH) 2010-10-13 — — EP disclosed
WO-2009092176-A2 METHOD OF FLAVORING GIVAUDAN SA (CH) 2009-07-30 — — WO disclosed
US-20090186138-A1 Method of Flavoring GIVAUDAN SA (CH) 2009-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186138-A1 Method of Flavoring TAS2R5, TAS2R50, TAS2R10 KMT2A 1234/4885MAPT 4717/4885MEN1 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback